相关临床试验
1291
149 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1365
终止
41
3.2%
招募中
247
19.1%
暂停
5
0.4%
撤回
30
2.3%
进行中（未招募）
107
8.3%
Unknown
220
17.0%
已完成
598
46.3%
Temporarily Not Available
1
0.1%
Enrolling By Invitation
4
0.3%
尚未招募
38
2.9%
暂无批准数据
- A 37-year-old dialysis-dependent patient with a cPRA of zero received a successful kidney transplant after 31 weeks of teclistamab therapy, a bispecific antibody originally approved for multiple myeloma. - The drug achieved a substantial and sustained reduction in HLA antibodies, converting previously unacceptable donor markers into acceptable ones — a feat unattainable with existing desensitization methods. - Published in the New England Journal of Medicine, the case study was led by researchers at the Medical University of Vienna and could herald a paradigm shift in transplant medicine. - An estimated 20–30% of kidney transplant waitlist patients are affected by significant HLA sensitization; further clinical studies are being planned to systematically assess benefits and risks.
- Europe's largest privately funded ME/CFS research programme is investing €2.4 million across seven new projects at eight German research institutions, including Charité Berlin and Heidelberg University Hospital. - Funded projects will investigate B-cell depletion therapy, genetic causes, biomarkers for diagnosis, autoimmunity, immunological mechanisms in children, and machine learning-assisted biomarker development. - ME/CFS affects over 657,000 people in Germany and more than 40 million worldwide, with 60–75% unable to work and no curative treatments currently available. - The DISCOVER-ME international project led by MedUni Vienna will analyze over 700 patient samples using multi-omics methods and screen 9,000 existing drugs for potential repurposing.
- A randomized Phase II trial across 13 European centers demonstrated that Torque-Teno virus (TTV)-guided tacrolimus dosing is non-inferior to standard immunosuppression in kidney transplant recipients. - The composite primary endpoint of infections, graft rejection, graft loss, or death occurred in 35% of the TTV-guided group versus 38% in the control group, with comparable rejection rates at 12 months. - Patients in the TTV-guided arm received lower tacrolimus doses and achieved lower drug levels, suggesting immunosuppression reduction may be possible without compromising organ safety in low-risk patients. - The study represents the first multicenter biomarker trial in organ transplantation to meet its primary endpoint and the first to control immunosuppression using a biomarker.
- About one in five patients taking GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro experience enhanced perception of sweetness and saltiness, which correlates with improved appetite control and satiety. - Participants who reported increased sweetness perception were twice as likely to experience enhanced satiety and 67% more likely to report reduced appetite compared to those with unchanged taste perception. - While taste changes don't directly correlate with BMI reduction, researchers suggest monitoring taste alterations could help clinicians assess treatment response and provide more personalized dietary guidance. - The study of 411 participants found significant weight loss across all three medications, with BMI reductions of 17.4% for Ozempic, 17.6% for Wegovy, and 15.5% for Mounjaro over treatment periods of 40-47 weeks.
- The HER3-directed antibody-drug conjugate patritumab deruxtecan achieved a 65% three-month overall survival rate in patients with leptomeningeal metastatic disease from solid tumors, meeting the primary endpoint of the TUXEDO-3 trial's cohort 3. - This represents the first prospective clinical trial investigating an antibody-drug conjugate specifically in patients with leptomeningeal metastases, a condition with historically poor prognosis and limited treatment options. - The treatment demonstrated manageable safety profile with no new neurological adverse events, while maintaining or improving patients' neurological symptoms and quality of life measures throughout the treatment period.
- Researchers from the Medical University of Vienna have discovered that PPAR𝛾, a protein targeted by type 2 diabetes medications, can influence prostate cancer cell growth. - The diabetes drug pioglitazone was found to inhibit tumor cell growth and metabolism in prostate cancer, suggesting potential repurposing opportunities for existing diabetes treatments. - Initial clinical observations indicate that prostate cancer patients with diabetes who received PPAR𝛾 agonists showed no cancer relapse during the study period, warranting further investigation.
- A novel pilot study demonstrates that respiratory function monitoring (RFM) significantly reduces the number of attempts needed for successful supraglottic airway device placement in neonates, including those under 1500g. - The study validated RFM effectiveness through bronchoscopy confirmation, showing that low leakage values on the monitor corresponded with correct anatomical placement of the device. - Healthcare providers achieved successful placement with fewer attempts (median: 1 vs 3) when using visible RFM guidance compared to hidden RFM, suggesting potential benefits for neonatal resuscitation protocols.
- A phase II pilot trial investigated very low doses of rituximab in patients with autoimmune hemolytic anemia (AIHA) to suppress CD20+ cell counts. - While initial infusions effectively depleted CD20+ cells, sustained depletion was not achieved across various low-dose regimens. - Rituximab plasma concentrations exceeding 0.4µg/mL correlated with CD20+ lymphocyte levels below detection limits, suggesting a potential efficacy threshold. - The study highlights the challenge of maintaining CD20+ cell suppression with very low-dose rituximab in AIHA, despite initial promising results.
- The major adverse cardiac events (MACE) endpoint, a long-standing standard in cardiovascular trials, is being questioned for its clinical relevance. - Critics argue that MACE inappropriately weights individual components and focuses excessively on early events, potentially obscuring the impact on patient well-being. - A new approach combining time-averaged quality of life with mortality, analyzed using the win ratio, is being explored as a more patient-centered endpoint. - The win ratio method aims to better reflect the overall impact of interventions on patients' lives, though some surgeons express concerns about its complexity and acceptance.
